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Abstract
BACKGROUND
Acromegaly is a chronic disease caused by a pituitary somatotroph adenoma
resulting in excess secretion of growth hormone, which leads to excess secretion
of Insulin like growth factor 1 from the liver, causing abnormal soft tissue
growth. There is increasing awareness that diseases affecting connective tissue
are associated with an increase in functional gastrointestinal symptoms. Data was
collected from patients with a confirmed diagnosis of acromegaly to evaluate the
intensity, variety and impact of abdominal symptoms in comparison with a
control group who were healthy participants recruited from the local fracture
clinic.
AIM
To evaluate the frequency type and burden of abdominal symptoms in
acromegaly in comparison with a control group.
METHODS
Medical documentation of patients with a diagnosis of acromegaly treated in one
tertiary medical centre between 2010 and 2017 has been analysed. Data was
collected from patients with confirmed acromegaly, using the Short Form Health
Survey (SF36) and Rome IV Diagnostic questionnaire for Functional
Gastrointestinal Disorders in Adults (R4DQ) and compared to a sex- and age-
matched control group, to assess the burden of abdominal symptoms. Microsoft
Excel and IBM SPSS v 25 were used for data analysis.
RESULTS
Fifty patients with acromegaly (24 male and 26 females; age range 23-64 years,
mean 43) and 200 controls (96 male and 104 females; age range 18-84, mean 42.4)
were recruited. 92% (46 out of 50) of patients with acromegaly reported
abdominal symptoms and 78% (39 out of 50) had at least one functional
gastrointestinal disorder according to the Rome IV diagnostic criteria, compared
to 16% of controls (OR > 1, P < 0.0001). The most commonly reported symptom
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was constipation (69% acromegaly vs 21% of controls OR > 1, P < 0.0001, 95%CI:
4.4–15.8). 34 out of 50 (68%) respondents met the criteria for functional
constipation according to Rome IV. Upper gastrointestinal disorders were also
more prevalent in the acromegaly group. There was no statistically significant
difference in the prevalence of biliary and anorectal symptoms between the two
groups. Patients in acromegaly group scored lower on the mean scores of the
eight parameters of SF36 Quality of Life questionnaire (mean scores 60.04 vs
71.23, 95%CI: -13.6829 to -8.6971, OR > 1, P < 0.001) as compared to the control
group.
CONCLUSION
Upper and lower functional gastrointestinal tract disorders (defined by Rome IV
diagnostic criteria) are significantly more prevalent in patients with acromegaly
compared with healthy age and sex matched controls in our study. Functional
constipation is the most commonly reported problem. Poorer quality of life may
in part be attributable to the increased prevalence of abdominal symptoms.
Key words: Functional gastrointestinal disorders; Acromegaly; Constipation; Irritable
bowel syndrome; Somatostatin; Pituitary
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core tip: Irritable bowel syndrome is the commonest cause of gastrointestinal symptoms.
The aetiology is thought to be multi-factorial but remains incompletely understood. Our
group has previously identified that patients with connective tissue disorders have an
increased incidence of functional gastrointestinal symptoms. Investigating for these
symptoms in patients with acromegaly may give further insight into the pathogenesis of
functional disorders and irritable bowel syndrome.
Citation: Inayet N, Hayat J, Bano G, Poullis A. Gastrointestinal symptoms in acromegaly: A
case control study. World J Gastrointest Pharmacol Ther 2020; 11(2): 17-24
URL: https://www.wjgnet.com/2150-5349/full/v11/i2/17.htm
DOI: https://dx.doi.org/10.4292/wjgpt.v11.i2.17
INTRODUCTION
Acromegaly is caused by a pituitary somatotroph adenoma and characterised by
excessive secretion of growth hormone (GH)[1,2]. GH stimulates the liver to produce
Insulin like growth factor 1 (IGF-1). In addition to the insulin-like effects, IGF-1 can
also regulate cellular DNA synthesis and is an important signalling molecule with
regards to cancer cell transformation and proliferation, including mitogenesis and
apoptosis inhibition[3].
A  variety  of  complications  have  been  reported  in  patients  with  acromegaly
including  cardiovascular  diseases,  such  as  hypertrophic  cardiomyopathy,  heart
failure, hypertension, diabetes mellitus or respiratory disorders, obstructive sleep
apnoea[4] as well as increased risk of benign and malignant neoplasms including colon
cancer[5].
The  organic  gastrointestinal  pathology  associated  with  acromegaly  such  as
increased risk  of  colonic  cancer  and an increased risk  of  cholelithiasis  has  been
studied in detail[6], however the issue of overall burden of gastrointestinal symptoms,
particularly the functional disorders in acromegaly and the gastrointestinal effects of
its treatment have not been well studied. We have previously identified how changes
in connective tissue in hypermobility (in Marfan and Ehlers Danlos) are associated
with an increase in functional gastrointestinal symptoms[7]. The impact of soft tissue
changes associated with over secretion of GH and gastrointestinal symptoms has not
previously been studied.
Somatostatin analogues used in the treatment of acromegaly are also associated
with a wide range of abdominal symptoms. Due to the higher risk of colon cancer,
acromegaly  patients  are  offered  screening  colonoscopy  during  which  standard
preparation for colonoscopy is often found inadequate, indicating functional and
structural change[5,8,9].
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Our aim was to evaluate gastro-intestinal symptoms in a cohort of acromegaly
patients. We assessed the frequency, character, severity and burden of abdominal
symptoms in patients with acromegaly in comparison with a control group.
MATERIALS AND METHODS
Patients
Medical documentation of patients with acromegaly treated in one medical centre
(Department of Endocrinology, St George’s Hospital, London) between 2010 and June
2017 have been analysed in  order  to  find the  information about  their  diagnosis,
treatment and presence of abdominal symptoms. Treatment information including
Somatostatin analogues and other medicines with significant gastrointestinal effects
were obtained from patients and controls. Selected patients were then asked to fill out
Rome IV Diagnostic questionnaire for Functional Gastrointestinal Disorders in Adults
(R4DQ) and SF36 questionnaire and were included as cases. Results were compared
with sex- and age-matched group of controls.
Controls
Participants  in  the  control  group  were  recruited  from  people  who  were  being
discharged from fracture clinic who were otherwise healthy and did not report any
other medical problems. Details of treatment history including drugs affecting the
gastrointestinal system were obtained.
Statistical analysis
Microsoft Excel and IBM SPSS v 25 were used to analyse the data. A case-control ratio
of 4:1 was used. Fisher’s exact test was used to analyse the results of R4DQ and one-
tailed Independent sample t test was used to analyse the mean scores of SF36. A P-
value under 0.05 was considered statistically significant.
Screening protocol
All patients had a confirmed diagnosis of acromegaly and were either post treatment
or undergoing treatment.
Ethics
The study protocol was approved by the South West-Central Bristol Research Ethics
Committee and NHS Health Research Authority United Kingdom.
RESULTS
Fifty patients with acromegaly (24 male and 26 females; age range 23-64 years, mean
43) and 200 controls (96 male and 104 females;  age range 18-84, mean 42.4) were
recruited in a 1:4 Case:Control ratio. The mean age at diagnosis of acromegaly was
32.44 years and on average participants had their diagnosis confirmed 11.8 years prior
to this study. All patients had trans-sphenoidal surgery and 21 (42%) had pituitary
radiotherapy  in  addition.  Thirty-seven  (74%)  patients  were  using  somatostatin
analogues (Table 1).
Ninety-two percent (46 out of 50) of patients with acromegaly reported abdominal
symptoms (abdominal pain, diarrhoea or constipation) and 78% (39 out of 50) had at
least  one  functional  gastrointestinal  disorder  (FGID)  according  to  the  Rome IV
diagnostic criteria,  compared to 16% of controls (OR > 1,  P  < 0.0001).  All  female
patients with acromegaly reported suffering from at least some abdominal symptoms
as  compared  to  87%  of  male  patients  with  acromegaly,  however  there  was  no
statistically significant gender difference observed in the frequency and intensity of
symptoms. The use of medicines (antacids, histamine receptor antagonists, proton
pump inhibitors,  laxatives)  used to alleviate gastrointestinal  symptoms was also
higher and statistically significant in the acromegaly group (Table 2).
A few patients  with  acromegaly  reported multiple  abdominal  symptoms and
qualified  for  more  than one  FGID.  The  most  commonly  reported symptom was
constipation (68% acromegaly group vs 7.5% of controls OR > 1, P < 0.0001, 95%CI:
4.4-15.8) followed by abdominal pain (22% acromegaly group vs 9.5% of controls OR >
1, P < 0.0001, 95%CI: 2.5-9.3). Thirty-four out of 50 (68%) respondents met the criteria
for functional constipation according to Rome IV. The prevalence of constipation
increased with increasing age and was often associated with bloating.  All  bowel
symptoms showed statistically significant prevalence in the acromegaly group. Some
oesophageal and gastroduodenal conditions such as functional heartburn, functional
WJGPT https://www.wjgnet.com June 9, 2020 Volume 11 Issue 2
Inayet N et al. Acromegaly and gastrointestinal symptoms
19
Table 1  Acromegaly demographic and treatment data
Controls Acromegaly patients
n 200 50
M:F 96:104 24:26
Age at diagnosis (mean, yr) 33 32.44
Years since diagnosis (mean, yr) - 11.8 yr
Transsphenoidal surgery - 50 (100%)
Pituitary radiotherapy - 21 (42%)
Somatostatin analogue - 37 (74%)
dysphagia and functional dyspepsia also showed statistically significant prevalence in
acromegaly group. There was no statistically significant difference of prevalence of
biliary and anorectal symptoms between the acromegaly group and controls (Table 3).
Acromegaly patients scored lower than controls on the mean scores of all eight
parameters measured by the SF36 quality of life index. These parameters include
physical functioning levels, role limitations due to physical health, role limitations
due  to  emotional  health,  energy/fatigue  levels,  emotional  wellbeing,  social
functioning levels, perception of pain and general health (mean scores 60.04 vs 71.23,
95%CI: -13.6829 to -8.6971, OR > 1, P < 0.001) (Table 4).
DISCUSSION
Acromegaly  is  a  rare  and  unique  disease  associated  with  abnormal  soft  tissue
growth[4] with a prevalence that is estimated at 40 per million in United Kingdom and
an annual incidence rate ranging between 2 and 11 cases per million per year, with an
equal distribution between genders[10].
Acromegaly is associated with gastrointestinal complications, such as constipation,
higher  prevalence  of  colorectal  polyps  and  cancer[11]  and  higher  prevalence  of
gallstones in patients treated with Somatostatin analogues[12]. Somatostatin analogues
used in the management of acromegaly are also associated with a wide range of
abdominal symptoms in addition to the known association with gallstones.
The higher prevalence of lower gastrointestinal symptoms in acromegaly could
partly be due to slow intestinal motility. Slow intestinal and colonic transit times have
been attributed to both acromegaly and its treatment with Somatostatin analogues.
Disease  related  slow  gut  motility  may  be  worsened  because  of  treatment  with
Somatostatin. Resmini et al[13]  demonstrated that patients with acromegaly have a
prolonged small intestinal transit time and a prolonged colon transit time. The small
bowel transit time calculated by standardized 10 g lactulose hydrogen breath test
showed significantly slower oro-caecal transit in patients than in controls, without
significant differences between patients treated with Somatostatin and untreated
patients.  These data suggest that acromegaly itself  may cause motility alteration.
However Thomas et al[14] performed radiological tests to investigate colonic transit and
found an increased transit time of colon (66% longer) in patients with acromegaly
compared with controls, and it was even more increased during octreotide treatment.
This may predispose to small intestinal bacterial overgrowth, which in turn can cause
symptoms[13]. Autonomic intestinal impairment due to vagal hypertonia, similar to
that demonstrated previously in the cardiovascular system, has been proposed as a
pathogenic mechanism[15]. Another proposed pathogenic mechanism could be related
to hormonal imbalance which can be influenced by the complex interaction between
GH and ghrelin,  as  shown by  Arosio  et  al[16].These  gut  motility  disturbances  in
acromegaly increase circulating levels of IGF-1, which is a known mitogen[17] that may
stimulate the proliferation of intestinal epithelial cells by autocrine and paracrine
actions[11].
Our study has also showed a higher prevalence of upper gastrointestinal symptoms
(functional  heartburn,  functional  dysphagia  and  functional  dyspepsia)  in  the
acromegaly group. Sisman et al[18] showed that the prevalence of gastritis, duodenitis,
peptic ulcers or intestinal metaplasia were higher in patients with acromegaly than in
healthy  subjects;  while  the  prevalence  of  hiatal  hernia  was  lower.  Ilhan  et  al[19]
demonstrated oesophageal dysmotility manifesting as profound reduction in the
amplitude  and  duration  of  lower  oesophageal  sphincter  relaxation  even  in
acromegaly patients without any significant gastrointestinal symptoms. George et al[20]
described a rare case of megaduodenum without any distal obstruction in a patient
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Table 2  Acromegaly abdominal symptoms and medicine use
Controls (n = 200) Acromegaly patients (n =50)
P value (Fisher’s exact
test)
Gastrointestinal symptoms 32 (16%) 46 (92%)
Abdominal pain 19 (9.5%) 11(22%) 0.4905
Diarrhoea 8 (4%) 4 (8%) 0.2652
Constipation 15 (7.5%) 34 (68%) < 0.00001b
Medicines
Regular use of anti-secretory
(PPI/H2RA)/antacids
11 (6.5%) 31 (62%) < 0.00001b
Regular use of laxatives 6 (3%) 46 (92%) < 0.00001b
Regular use of opioid
analgesics
11 (6.5%) 2 (4%) Not statistically significant
Somatostatin analogues - 37 (74%)
bP < 0.01, statistically significant. PPI: Proton pump inhibitor; H2RA: Histamine H2 receptor antagonists.
with  acromegaly.  Somatostatin  analogues  inhibitory  effect  on  gut  motility,
particularly antral contractility may also produce or worsen symptoms in patients
with delayed gastric emptying[21].
Despite  our  study  not  showing  any  statistically  significant  difference  in  the
prevalence of  biliary symptoms in the two groups,  other studies have shown an
increased risk of gall stones in acromegaly[22-24]. The increased risk of faecal anaerobic
bacteria  overgrowth associated with  slow gut  transit  times,  with  the  additional
increased risk of impairment of bile acid metabolism may be responsible in part for
gallstone development[14].  Ultrasound studies have found increased gall  bladder
volume in both fasting and postprandial states in acromegaly. These are associated
with profound suppression of released cholecystokinin, which is associated with
Somatostatin  administration.  The incomplete  gall  bladder  emptying may be  the
reason for higher incidence of gall bladder calculi in patients with acromegaly treated
with Somatostatin[12].
This study is the first study in our knowledge that looks into the prevalence of
various  abdominal  symptoms  in  acromegaly.  The  burden  of  non-organic
gastrointestinal symptoms, particularly the functional disorders in acromegaly and
the gastrointestinal effects of its treatment have not been well studied. This study,
along with our previous studies on Marfan and Ehlers Danlos[7] gives insight into the
possible link between connective tissue abnormalities and irritable bowel syndrome
(IBS). IBS is the commonest final diagnosis in patients presenting with gastrointestinal
symptoms. The aetiology is multifactorial. This study gives further evidence to the
suggestion that connective tissue abnormalities may be the underlying pathology in
some individuals with IBS.
The strengths of this study are that for a very rare condition this is a large patient
cohort  being looked after in one tertiary hospital,  with a large control  group for
comparison. A weakness of this study is that cases were not clinically reviewed to
ensure  that  symptoms  had  been  fully  investigated  to  ensure  that  the  symptom
complex was truly functional. Also, it was not possible to analyse for disease duration
prior to diagnosis, treatment administered historically, on-going treatment and time
since diagnosis were not possible.
The presence of FGIDs affecting both upper and lower gastrointestinal tract in
patients with acromegaly is substantially higher than the controls in our study. The
lower mean scores on quality of life indicators in the acromegaly group reflect the
overall  burden  of  disease  on  quality  of  life.  The  high  prevalence  of  abdominal
symptoms may in part explain this. This is likely to be multifactorial and factors such
as delayed small intestinal and colonic transit times, treatment with Somatostatin
analogues, increased bowel length may all play a part in this. A larger follow up
international  multi-centre  study  on  the  presence  of  abdominal  symptoms  in
acromegaly and future clinical research focussing on the association of abdominal
symptoms with connective tissue abnormalities may further help our understanding
of IBS and other FGIDs.
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Table 3  Gastrointestinal symptoms in acromegaly patients compared with controls
Controls, n = 200 (%) Acromegaly patients, n =50 (%)
P value (Fisher’s exact
test)
Oesophageal disorders
Functional chest pain 2 (1%) 3 (6%) 0.0561
Functional heartburn 22 (11%) 15 (30%) 0.0016b
Globus 2 (1%) 2 (4%) 0.1796
Functional dysphagia 4 (2%) 6 (12%) 0.0053b
Gastroduodenal disorders
Functional dyspepsia 14 (7%) 12 (24%) 0.0013b
Belching disorders 8 (4%) 5 (10%) 0.1441
Nausea and vomiting
disorders
2 (1%) 2 (4%) 0.1796
Rumination syndrome 2 (1%) 1 (2%) 0.4895
Bowel disorders
Irritable bowel syndrome 12 (6%) 10 (20%) 0.0041b
Functional constipation 22 (11%) 34 (68%) 0.0006b
Functional diarrhoea 10 (5%) 9 (18%) 0.0048b
Functional abdominal
bloating/distension
12 (6%) 11 (22%) 0.0015b
Unspecified functional bowel
disorder
44 (22%) 25 (50%) 0.0002b
Centrally mediated
Abdominal pain syndrome
6 (3%) 4 (8%) 0.1165
Functional Biliary pain 1 (0.5%) 3 (6%) 0.0261a
Anorectal disorders
Faecal incontinence 1 (0.5%) 2 (4%) 0.1028
Functional anorectal pain 2 (1%) 4 (8%) 0.0157a
aP < 0.05,
bP < 0.01, statistically significant.
Table 4  Quality of life scores in acromegaly patients
Controls (mean scores) Acromegaly (mean scores) Independent sample t test
Physical functioning 100.0 80.0 0.80516
Role limitations due to physical health 100.0 50.0 0.001053b
Role limitations due to emotional problems 100.0 100.0 1
Level of energy/fatigue 95.0 45.0 0.001053b
Emotional wellbeing 100.0 68.0 0.002175b
Social functioning 87.5 50.0 < 0.000076b
Pain 77.5 67.5 0.1732
General health 100 30.0 < 0.0001b
bP < 0.01, statistically significant.
ARTICLE HIGHLIGHTS
Research background
Acromegaly results from an excess of growth hormone, which leads to excess secretion of Insulin
like growth factor 1 from the liver, causing abnormal soft tissue growth. This is associated with
an increase in a number of organic diseases. There is increasing awareness that diseases affecting
connective tissue are associated with an increase in functional gastrointestinal symptoms. We are
not  aware  of  any other  study that  has  looked into  the  burden of  abdominal  symptoms in
acromegaly and the impact they have on patient’s quality of life as a result of this.
Research motivation
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This study is part of a larger study that is assessing the role and significance of connective tissue
involvement in abdominal symptoms. We have previously described an increase in functional
gastrointestinal symptoms in other diseases affecting connective tissue (Marfan and Ehlers
Danlos).  In this  study we evaluate the frequency of  abdominal  symptoms in patients with
acromegaly.
Research objectives
The main objective of this study was to evaluate if patients with acromegaly had more frequent
and intense abdominal symptoms, as described by the Rome criteria, than controls and thus, as a
result of this had poorer quality of life. Furthermore, other factors such as use of Somatostatin
analogues, which in itself can cause abdominal symptoms, had to be taken into account. The next
step in our research would be to carry out objective gastrointestinal physiological studies in
larger  groups  of  patients  and  controls  to  see  if  the  presence  of  symptoms  reflects  actual
physiological variations across different groups.
Research methods
Patients with acromegaly were identified from a clinical database at one tertiary medical centre
(Department of Endocrinology, St George’s Hospital, London). Identified patients were then
asked to fill out previously validated questionnaires and results were compared with sex- and
age-matched group of controls (recruited from fracture clinic who were otherwise healthy and
did not report any other medical problems).
Research results
The results of this study showed that the presence of abdominal symptoms in acromegaly is
significantly higher than controls. The results also show that the presence of these symptoms has
an overall  detrimental  effect  on quality of life or well  being of the patient.  This study also
supports the increasing awareness in the scientific world regarding the association of connective
tissue  abnormalities  and  gastrointestinal  or  abdominal  symptoms.  It  is  yet  to  be  seen  if
gastrointestinal physiological studies in these patients will be reflective of these results.
Research conclusions
The presence  of  abdominal  symptoms is  significantly  higher  in  patients  with  acromegaly
compared to controls and this may have a significant impact on their quality of life. Connective
tissue abnormalities are associated with abdominal symptoms as has been shown by this study
and other studies and may be one of the underlying reasons behind functional gastrointestinal
disorders  (FGIDs).  Other studies  have shown similar  results  in Ehlers-Danlos and Marfan
syndromes and abnormalities of connective tissue such as elastin may be common to these
disease processes. This needs to be studied further to see if minor variations in gut connective
tissue the cause of FGIDs could be.
Research perspectives
Future research in this area will have to be pursued in an international and multicentre study as
it is difficult for one centre to recruit a large number of patients in rare diseases. Gastrointestinal
physiological studies would help to see if the variance in symptoms is reflected in physiological
variance.
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